Collegium Pharmaceutical, Inc. COLL
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -48.60%
- 1 year
- -33.24%
- Open
- 24.28
- Prev close
- 24.03
- Mkt cap
- 774.82M
- Vol
- 401.93K
- Avg vol
- 818.57K
- EPS
- 1.27
- P/E
- 18.74
- Div yield
- 0.00%
More statistics
- Low
- 23.66
- High
- 24.50
- Forward P/E
- 4.86
- Beta
- 0.73
- Short ratio
- 0.00
- Inst. own
- 128.23%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 34.80
- 200-d avg
- 39.23
- 1y target
- 53.60
5D chart
Signals (103)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 9:30 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 9:30 AM | 1 day ago |
| RSI: Overbought | Oct 30, 9:30 AM | 1 day ago |
| MACD: Sell Signal | Oct 29, 4:00 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:25 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:25 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:00 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:35 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:35 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:25 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:25 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:05 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:10 PM | 2 days ago |
| RSI: Overbought | Oct 29, 11:05 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:55 AM | 2 days ago |
| RSI: Overbought | Oct 29, 10:20 AM | 2 days ago |
| RSI: Overbought | Oct 29, 10:10 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 2 days ago |
| MACD: Buy Signal | Oct 28, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:55 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:45 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:40 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:35 PM | 3 days ago |
| RSI: Overbought | Oct 28, 2:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:00 PM | 3 days ago |
| RSI: Overbought | Oct 28, 2:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 1:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:35 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 1:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:15 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 11:10 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 11:10 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:05 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:00 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:55 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:15 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 10:15 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:10 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 27, 3:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:10 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:05 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:40 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 2:15 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:00 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:00 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 11:50 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:40 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:40 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 10:40 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:35 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:55 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 9:55 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 9:50 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 9:40 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 26, 3:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:25 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:20 PM | 5 days ago |
| RSI: Oversold | Oct 26, 2:55 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:30 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:15 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 12:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 12:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 5 days ago |
| SMA: Bullish | Oct 26, 11:10 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:45 AM | 5 days ago |
News
2 days ago zacks.com
Earnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to Decline
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2 days ago globenewswire.com
Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts
New multi-year partnership combines youth coach training, an annual Sports for All Summit, and sensory inclusion programs to support neurodivergent children and families New multi-year partnership…
1 week ago globenewswire.com
Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026
STOUGHTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and…
1 week ago globenewswire.com
Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses
Seven presentations include pediatric Phase 4 studies of AZSTARYS® (Serdexmethylphenidate/dexmethylphenidate) CII and real-world research of JORNAY PM® (Delayed-Release/Extended-Release…
-
1 week ago benzinga.com
Collegium Pharmaceutical And Grünenthal Enter Settlement Agreement On Oct 15, 2026; Terminates Grünenthal License And Consent Agreement For Territory Effective Oct 15, 2026; Co. To Pay Grünenthal $17M In Settlement
As previously disclosed, Collegium Pharmaceutical, Inc. (the "Company") is party to a License Agreement (U.S.), dated as of January 13, 2015, with Grünenthal GmbH ("Grünenthal") (as amended, the
1 week ago zacks.com
COLL vs. DSNKY: Which Stock Is the Better Value Option?
Investors interested in Medical - Drugs stocks are likely familiar with Collegium Pharmaceutical (COLL) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
2 weeks ago seekingalpha.com
Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut
Collegium Pharmaceutical is rated a high-risk Buy after a sharp guidance cut and stock drop, with the market pricing in an overly pessimistic scenario. ADHD drugs Jornay PM and AZSTARYS now account…
2 weeks ago zacks.com
Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?
The consensus price target hints at an 111.4% upside potential for Collegium Pharmaceutical (COLL). While empirical research shows that this sought-after metric is hardly effective, an upward trend…
3 weeks ago zacks.com
New Strong Sell Stocks for October 7th
ARDX, LUV and COLL have been added to the Zacks Rank #5 (Strong Sell) List on October 7th, 2026.
3 weeks ago globenewswire.com
Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life
STOUGHTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and…
3 weeks ago benzinga.com
Collegium Pharmaceutical Reports Q2 2026 Results: Full Earnings Call Transcript
Collegium Pharmaceutical (NASDAQ:COLL) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs.…
-
1 month ago benzinga.com
Oppenheimer Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $50
Oppenheimer analyst Les Sulewski initiates coverage on Collegium Pharmaceutical (NASDAQ:COLL) with a Outperform rating and announces Price Target of $50.
1 month ago seekingalpha.com
Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
-
1 month ago benzinga.com
Truist Securities Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $49
Truist Securities analyst Alexander Xenakis maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $58 to $49.
-
1 month ago benzinga.com
Leerink Partners Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $45
Leerink Partners analyst Daniel Clark initiates coverage on Collegium Pharmaceutical (NASDAQ:COLL) with a Outperform rating and announces Price Target of $45.
1 month ago globenewswire.com
Collegium to Participate in Upcoming Investor Conferences
STOUGHTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious…
1 month ago benzinga.com
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In Q3
Healthcare stocks UTHR, COLL and AHG show oversold RSI levels near or below 30, potentially offering undervalued buying opportunities.
2 months ago defenseworld.net
44,493 Shares in Collegium Pharmaceutical, Inc. $COLL Purchased by Freestone Grove Partners LP
Freestone Grove Partners LP bought a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL) in the second quarter, according to its most recent 13F filing with the Securities and…
2 months ago defenseworld.net
BlackRock Inc. Takes $196.97 Million Position in Collegium Pharmaceutical, Inc. $COLL
BlackRock Inc. bought a new position in Collegium Pharmaceutical, Inc. (NASDAQ: COLL) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange…
2 months ago gurufocus.com
A Look at Collegium Pharmaceutical Inc (COLL) After 3.9% Decline -- GF Value $47.17 vs Price $26.39
On August 27, 2026, Collegium Pharmaceutical Inc (COLL) shares fell 3.9% to a current price of $26.39. Over the past year, the stock has seen significant volati
-
2 months ago benzinga.com
Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $48
Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight and lowers the price target from $56 to $48.
2 months ago globenewswire.com
Collegium Announces $50 Million Accelerated Share Repurchase Program
STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and…
2 months ago defenseworld.net
Avenue Therapeutics (NASDAQ:ATXI) and Collegium Pharmaceutical (NASDAQ:COLL) Head-To-Head Survey
Collegium Pharmaceutical (NASDAQ: COLL - Get Free Report) and Avenue Therapeutics (NASDAQ: ATXI - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will…
-
2 months ago benzinga.com
Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $43
Piper Sandler analyst David Amsellem reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Neutral and lowers the price target from $45 to $43.
2 months ago seekingalpha.com
Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript
Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript
-
2 months ago benzinga.com
Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $46
Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $56 to $46.
2 months ago zacks.com
Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare…
2 months ago zacks.com
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.92 per share, beating the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $1.68 per share a year ago.
2 months ago marketbeat.com
Collegium Pharmaceutical Q2 Earnings Call Highlights
Collegium Pharmaceutical NASDAQ: COLL reported second-quarter 2026 net product revenue of $199.9 million, up 6% from a year earlier, as growth in its ADHD franchise and BELBUCA helped offset lower…
-
2 months ago benzinga.com
Collegium Pharmaceutical Lowers FY2026 Sales Guidance from $865.000M-$895.000M to $825.000M-$855.000M vs $872.278M Est
Collegium Pharmaceutical (NASDAQ:COLL) lowers FY2026 sales outlook from $865.000 million-$895.000 million to $825.000 million-$855.000 million vs $872.278 million estimate.
-
5 months ago benzinga.com
Collegium Pharmaceutical Affirms FY2026 Sales Guidance of $805.000M-$825.000M vs $825.757M Est
Collegium Pharmaceutical (NASDAQ:COLL) affirms FY2026 sales outlook from $805.000 million-$825.000 million to $805.000 million-$825.000 million vs $825.757 million estimate.
-
5 months ago benzinga.com
Collegium Pharmaceutical Q1 Adj. EPS $1.76 Beats $1.59 Estimate, Sales $193.520M Beat $185.984M Estimate
Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly earnings of $1.76 per share which beat the analyst consensus estimate of $1.59 by 10.69 percent. This is a 18.12 percent increase over…
8 months ago benzinga.com
Earnings Scheduled For February 26, 2026
Earnings Scheduled For February 26, 2026
11 months ago benzinga.com
Earnings Scheduled For November 6, 2025
Earnings Scheduled For November 6, 2025
-
1 year ago benzinga.com
Earnings Scheduled For February 27, 2025
Earnings Scheduled For February 27, 2025
-
2 years ago benzinga.com
Earnings Scheduled For February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.
-
2 years ago benzinga.com
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
-
3 years ago benzinga.com
Atlassian, Universal Display, Booking, Dropbox And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Friday. Here are some big stocks recording gains in today’s session.
-
3 years ago benzinga.com
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
-
3 years ago benzinga.com
Earnings Scheduled For May 4, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.
-
3 years ago benzinga.com
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
-
3 years ago benzinga.com
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
-
4 years ago benzinga.com
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
-
4 years ago benzinga.com
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 435 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 213 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
During Thursday, 849 stocks hit new 52-week lows.